Kushwaha S - Search Results

1

Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade.

Bishu K, Ogut O, Kushwaha S, Mohammed SF, Ohtani T, Xu X, Brozovich FV, Redfield MM. Bishu K, et al. Among authors: kushwaha s. PLoS One. 2013 Dec 3;8(12):e81325. doi: 10.1371/journal.pone.0081325. eCollection 2013. PLoS One. 2013. PMID: 24312548 Free PMC article.

2

Long-term maintenance therapy for post-cardiac transplant monoclonal lymphoproliferative disorder: caveat mammalian target of rapamycin.

Khalpey Z, Miller DV, Schmitto JD, Kushwaha SS. Khalpey Z, et al. Among authors: kushwaha ss. Transplant Proc. 2011 Jun;43(5):1893-9. doi: 10.1016/j.transproceed.2011.03.033. Transplant Proc. 2011. PMID: 21693296

3

Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish.

Ding Y, Sun X, Huang W, Hoage T, Redfield M, Kushwaha S, Sivasubbu S, Lin X, Ekker S, Xu X. Ding Y, et al. Among authors: kushwaha s. Circ Res. 2011 Sep 2;109(6):658-69. doi: 10.1161/CIRCRESAHA.111.248260. Epub 2011 Jul 14. Circ Res. 2011. PMID: 21757652 Free PMC article.

4

Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics.

Ding Y, Sun X, Redfield M, Kushwaha S, Xu X. Ding Y, et al. Among authors: kushwaha s. Cell Cycle. 2012 Feb 1;11(3):428-9. doi: 10.4161/cc.11.3.19164. Epub 2012 Feb 1. Cell Cycle. 2012. PMID: 22262179 Free PMC article. No abstract available.

5

Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies.

Kushwaha S, Xu X. Kushwaha S, et al. Trends Cardiovasc Med. 2012 Feb;22(2):39-43. doi: 10.1016/j.tcm.2012.06.009. Epub 2012 Jul 28. Trends Cardiovasc Med. 2012. PMID: 22841839 Free PMC article. Review.

6

Pulmonary Pressure Assessment with the Total Artificial Heart.

Joyce DL, Redfield MM, Kushwaha SS, Behfar A, Borlaug BA, Daly RC, Sandhu GS, Joyce LD. Joyce DL, et al. Among authors: kushwaha ss. ASAIO J. 2018 May/Jun;64(3):e34-e36. doi: 10.1097/MAT.0000000000000632. ASAIO J. 2018. PMID: 28742532

7

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS. Kushwaha SS, et al. J Heart Lung Transplant. 2005 Dec;24(12):2129-36. doi: 10.1016/j.healun.2005.08.015. J Heart Lung Transplant. 2005. PMID: 16364861 Clinical Trial.

8

Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy.

Bae JH, Rihal CS, Edwards BS, Kushwaha SS, Mathew V, Prasad A, Holmes DR Jr, Lerman A. Bae JH, et al. Among authors: kushwaha ss. Transplantation. 2006 Oct 27;82(8):1108-11. doi: 10.1097/01.tp.0000230378.61437.a5. Transplantation. 2006. PMID: 17060862

9

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.

Raichlin E, Bae JH, Khalpey Z, Edwards BS, Kremers WK, Clavell AL, Rodeheffer RJ, Frantz RP, Rihal C, Lerman A, Kushwaha SS. Raichlin E, et al. Among authors: kushwaha ss. Circulation. 2007 Dec 4;116(23):2726-33. doi: 10.1161/CIRCULATIONAHA.107.692996. Epub 2007 Nov 19. Circulation. 2007. PMID: 18025531 Clinical Trial.

10

Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients.

Kushwaha SS, Raichlin E, Sheinin Y, Kremers WK, Chandrasekaran K, Brunn GJ, Platt JL. Kushwaha SS, et al. Eur Heart J. 2008 Nov;29(22):2742-50. doi: 10.1093/eurheartj/ehn407. Epub 2008 Sep 11. Eur Heart J. 2008. PMID: 18790727 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

604 results

Search Page

Filters